search
for
 About Bioline  All Journals  Testimonials  Membership  News  Donations


Australasian Biotechnology (backfiles)
AusBiotech
ISSN: 1036-7128
Vol. 8, No. 5, 1998
Bioline Code: au98039
Full paper language: English
Document type: Research Article
Document available free of charge

Australasian Biotechnology (backfiles), Vol. 8, No. 5, 1998

 en Biotechnologies Applied to the Production of Pharmaceuticals and Vaccines: A Summary

Abstract

Australasian Biotechnology,
Volume 8 Number 5, September/October 1998, pp. 303-305

CONFERENCE PAPER

Biotechnologies Applied to the Production of Pharmaceuticals and Vaccines: A Summary

A. Sasson,

Code Number:AU98039
Sizes of Files:
Text: 13K
Graphics: No associated graphics files

In 1973, Stanley Cohen of Stanford University, Herbert Boyer of the University of California Medical School (San Francisco), and their colleagues succeeded in designing the method for the transfer of a gene from one organism to another, thus establishing the basis of recombinant DNA technology. In 1981, the first US-approved biotechnology product reached consumers: a monoclonal antibody-based diagnostic test kit. The following year, the first recombinant DNA pharmaceutical, Genentech Incs.'s (Eli Lilly & Co.) Humulin®, recombinant human insulin, was approved for sale in the USA and United Kingdom. That same year, the first recombinant animal vaccine against colibacillosis was approved in Europe.

Copyright 1998 Australian Biotechnology Association Ltd.

 

Alternative site location: http://www.ausbiotech.org/content.asp?pageid=16

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2020, Site last up-dated on 09-Nov-2020.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil